Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
B- doesnt seem bad to me...
Their site has information on how they rate these things. Been watching CHND since late last year, they seemed to put this deal together the right way.
http://www.ludlowchina.com/reports/about.html
CBPC - .073 x .074 (upgraded)
check out their recent PR's....real deal company.
CBPC - .0724 x .0725 (upgraded)
Ludlow China Upgrades China Biopharma, Inc.
Monday June 18, 8:00 am ET
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Ludlow China upgrades China Biopharma, Inc. (OTC Bulletin Board: CBPC - News) from a C to B- rating based on a recent guidance for fiscal year 2007 issued by the company. On June 13, 2007, the company issued revenue guidance for fiscal year 2007 of between $10 million to $13 million, with projected positive net income. Based on a price to sales (P/S) ratio of just 3 times sales that would give CBPC a valuation of $30 to $39 million. With around 90 million shares outstanding, that would give CBPC a potential target of around $0.30 to $0.40 a share.
INVESTMENT HIGHLIGHTS
-- Market Growth - the market in China for flu vaccinations has grown from
3.9 million doses in 2000 to 22.3 million doses in 2005, or 30% year
over year.
-- Distribution Network - the company has the largest independent vaccine
distribution network covering 268 cities in China.
-- Strategic Alliances - the company retains a close relationship with the
Chinese Center of Disease Control (CDC), providing local CDC
vaccinations, and providing their high-capacity production facility for
any potential epidemics within China.
-- Product Pipeline - in addition to marketing vaccines for Influenza,
Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the
company is also conducting research such new products to cover
allergies and avian bird flu.
-- Revenue Projection - management anticipates generating $10 to $13
million in annual revenues and positive net income for fiscal year
2007.
-- Management Experience - the company retains some of the top scientists
within the human vaccine fields in China, and has had a number of years
experience running a public company.
For a link to the full investment opinion, and risks associated with this company visit - http://www.ludlowchina.com/reports/cbpc.htm
GRSR vs. WWAT
Seen that WWAT has been rockin, and so did a quick camparison between both.
For 2006
Revenues
WWAT = $17.1 million
GRSR = $60 million
Gross Profit
WWAT = $2.7 million
GRSR = $1.1 million
Net Loss
WWAT = ($11.4 million)
GRSR = ($360k)
EPS
WWAT = ($0.08)
GRSR = ($0.00)
Shares Outstanding
WWAT = 135 million
GRSR = 35 million
Share Price
WWAT = 1.10
GRSR = 0.37
* We're closer to profit then WWAT.
could test the 50 day MA
GRSR hasnt been above its 50 day MA since Feb 2007, and just has to break above .39
http://stockcharts.com/h-sc/ui?s=GRSR&p=D&yr=0&mn=6&dy=0&id=p33443978555
Also expecting 10K anytime now. Come auditers....file it!
risk note
Risk Note: This projected formula is based on 90 million shares outstanding, and depending on future dilution these targets can change. The company currently has a convertible note outstanding, and thus has some issues to work through before any determined move upward. Another risk factor would be the company's inability to meet revenue targets going forward.
Ludlow China is recommending CBPC as a 'speculative high risk' equity.
republicans blocking energy bill
WASHINGTON - Three powerful lobbying forces — automakers, electric utilities and the coal industry — are confounding Democrats' efforts to forge a less-polluting energy policy.
Disputes over automobile fuel economy, use of coal as a motor fuel, and requirements for utilities to use more wind or biomass to generate electricity have threatened to stall energy legislation in both the Senate and House.
An intense GOP fight against the proposal has been waged largely at the behest of two of the country's biggest coal-burning electricity producers — the Atlanta-based Southern Company and the Tennessee Valley Authority.
http://news.yahoo.com/s/ap/20070618/ap_on_go_co/congress_energy;_ylt=AszGzQEDmLbrkXmOAJLcd6qs0NUE
surprised not more around...
nice volume over the past few trading days, kind of surprised we dont see more people or at least flippers posting about. Bidded some down here, but would like to see it move above .10 before any real commitment. Wait until the convertable note gets done.
Ludlow China - CHCG to $10...
Ludlow China Upgrades Coverage on China 3C Group, 12 Month Target of $10.00 a Share, and A- Rating
Last Updated: May 16, 2007
http://www.ludlowchina.com/reports/chcg.htm
They may be too low IMO. I'm thinking in 12 months you could be looking at a $15 to possibly even $20 stock, but $15 more likely.
dont know about .40, but could be a play up to .15 or .20 Really all depends on how much of this note they have to go through before it moves up. See they mentioned it as a risk factor.
Ludlow China rates CHND B-
http://www.ludlowchina.com/reports/index.html
avian bird flu
-- Product Pipeline - in addition to marketing vaccines for Influenza,Epidemic Hemorrhagic Fever, and Epidemic Japanese Encephalitis, the company is also conducting research such new products to cover allergies and avian bird flu.
------------
HANOI, June 18 (Reuters) - Bird flu, which has killed one person since it re-emerged in Vietnam in early May, has flared up on several farms in a northern province despite efforts by the government to ...
http://news.search.yahoo.com/news/search?p=bird+flu&c=
CBPC moving on Upgarde ++++++
Ludlow China Upgrades China Biopharma, Inc.
Monday June 18, 8:00 am ET
PRINCETON, N.J., June 18 /PRNewswire-FirstCall/ -- Ludlow China upgrades China Biopharma, Inc. (OTC Bulletin Board: CBPC - News) from a C to B- rating based on a recent guidance for fiscal year 2007 issued by the company. On June 13, 2007, the company issued revenue guidance for fiscal year 2007 of between $10 million to $13 million, with projected positive net income. Based on a price to sales (P/S) ratio of just 3 times sales that would give CBPC a valuation of $30 to $39 million. With around 90 million shares outstanding, that would give CBPC a potential target of around $0.30 to $0.40 a share.
http://finance.yahoo.com/q?s=CBPC.OB
Ludlow China Index + 58%
Ludlow China Index Returns 58% Over Past 12 Month
June 16, 2007 - 2:43pm EST
NEW YORK--(Ludlow China)--Ludlow China Ventures announced that the Ludlow China Large Cap Index has returned more then 58% over the past 12 months.
The Ludlow China Index was launched with a starting index value of around 2,400 in early June 2006. As of the close of Friday June 15, 2007, the Ludlow China index closed at 3,815.41, up 1,400+ points, or a performance of around 58% return over the past 12 months.
Full Article - http://www.ludlowchina.com/news/june07.html
Ludlow China Index + 58%
Ludlow China Index Returns 58% Over Past 12 Month
June 16, 2007 - 2:43pm EST
NEW YORK--(Ludlow China)--Ludlow China Ventures announced that the Ludlow China Large Cap Index has returned more then 58% over the past 12 months.
The Ludlow China Index was launched with a starting index value of around 2,400 in early June 2006. As of the close of Friday June 15, 2007, the Ludlow China index closed at 3,815.41, up 1,400+ points, or a performance of around 58% return over the past 12 months.
Full Article - http://www.ludlowchina.com/news/june07.html
SEC Approves Changes To Short-Selling Rules
(In fourth paragraph, update notes that termination of "grandfather" clause becomes effective 60 days after publication in Federal Register; 12th paragraph adds extension for previously restricted stocks.)
By Judith Burns
Of DOW JONES NEWSWIRES
WASHINGTON -(Dow Jones)- The Securities and Exchange Commission voted Wednesday to abolish longstanding rules that restrict short sales in declining markets and to tighten rules intended to curb manipulative short sales, including so-called "naked" short sales.
The first change, approved in a 5-0 vote, ends decades-long restrictions by the SEC and U.S. markets on selling short as prices are falling. An experiment in lifting the rules for select stocks showed there was little justification for retaining restrictions such as the New York Stock Exchange's "tick" test, SEC Chairman Christopher Cox said.
Elimination of SEC's short-sale price restrictions and rules barring markets from using a "tick" or "bid" test to control short sales will take effect immediately after the rule change is published in the Federal Register, SEC staffers said. Barriers to short sales as prices are moving lower date from the 1930s, when regulators sought to prevent "bear" raids that could send prices spiraling downward. The advent of decimal trading has made it harder to comply with such restrictions, and with better market surveillance, "we've determined that the rule simply is not needed," said SEC Commissioner Paul Atkins.
A second change approved by the SEC modifies its Regulation SHO, adopted in 2004 to curb abusive short sales. The SEC voted unanimously Wednesday to eliminate a controversial exception to the 2004 rule that shielded existing short positions from a requirement to deliver hard-to-borrow shares within 13 days of settlement. Once the change takes effect, 60 days after publication in the Federal Register, short positions previously protected by the grandfather clause must be closed out within 35 days.
Short selling involves sales of borrowed securities, producing profits when prices decline. The practice is legal, but the SEC's Regulation SHO sought to prevent "naked" short sales, in which short sellers don't borrow securities they sell. Among other things, the SEC regulation, which took effect in 2005, imposed new deadlines on closing out short positions by delivering borrowed shares.
SEC officials said delivery failures have declined about 35% overall since Regulation SHO took effect and have fallen about 53% for hard-to-borrow stocks defined as "threshold" securities.
Longstanding, persistent delivery failures seem to be due to the grandfather protections and a similar shield for short positions of option market makers, and may be a sign of naked short selling, said Cox.
"It continues to be a problem, particularly in the microcap space," Cox told reporters after the SEC meeting.
SEC Commissioner Annette Nazareth said ending the grandfather protections won't have adverse effects, such as volatile trading, that prompted the SEC to adopt the shield in 2004. SEC Commissioner Kathleen Casey also endorsed the change, saying the benefit of doing so more than offsets concerns that a " squeeze" on outstanding short positions might roil stock markets.
To shed light on delivery failures, the SEC plans to make aggregate Depository Trust Co. data available on the SEC Web site shortly, after removing certain confidential information from the data feed already supplied to regulators by the DTC. Agency staffers said providing hard data on delivery failures may reduce the number of requests the SEC has received for such data under the Freedom of Information Act.
Protections for options market makers remain up in the air. The SEC abandoned earlier plans to narrow such protections and voted Wednesday to seek comment on eliminating the exception altogether, or adopting an alternative approach. One alternative would set a 35-day delivery requirement on short sales to hedge option series established before a stock is designated as a threshold security. A second would set the delivery deadline at 35 days or 13 days after the expiration of all options series in a portfolio, whichever is earlier.
Additionally, the SEC extended the deadline to close out short positions on previously restricted stock, allowing 35 days, rather than 13, and adopted a requirement for brokers marking a sale as an outright "long" sale to document the location of the shares being sold. The SEC also modified an exception from short-selling restrictions for unwinding net short index-arbitrage positions, available provided the market hasn't declined by 2% or more from the prior day's close, based on a market index. The SEC voted to substitute the New York Composite Index for the Dow Jones Industrial Average as the applicable market- decline index.
In a last-minute change, the SEC deferred action on a fourth rule that would have tightened short sales in connection with public offerings, but Cox said it plans to take up the matter shortly, perhaps later this month.
Look at price to sales ratios...
..on these other vaccine producers.
NVAX = 46
AVII - 264
VICL = 18
GNBT = 764
HEB - 105
SVA = 7
CBPC = 5
If CBPC can do just 2 times projected sales that would be $20 million market cap. At a current market cap of like $6 million CBPC could have some upside.
But, the question is, how much paper they giving out and how bad will the dilution will be. That we not know for sure until next 10Q.
dilution risks
least it seems Ludlow has pointed out the risks somewhat.
COVERAGE SUMMARY
Ludlow China has upgraded CBPC from a C to B- rating based on guidance for 2007 issued by the company. On June 13, 2007, the company issued revenue guidance for fiscal year 2007 of between $10 million to $13 million, with projected positive net income. Based on a price to sales (P/S) ratio of just 3 times sales that would give CBPC a valuation of $30 to $39 million. With around 90 million shares outstanding, that would give CBPC a potential target of around $0.30 to $0.40 a share.
Risk Note: This projected formula is based on 90 million shares outstanding, and depending on future dilution these targets can change. The company currently has a convertible note outstanding, and thus has some issues to work through before any determined move upward. Another risk factor would be the company's inability to meet revenue targets going forward.
Ludlow China is recommending CBPC as a 'speculative high risk' equity.
http://www.ludlowchina.com/reports/cbpc.htm
Ludlow Dragon Index - CHCG
CHCG is in the Ludlow Dragon Index which seems to reflect the core holdings of their managed China fund.
http://www.ludlowchina.com/indices/dragon.html
----------
The Ludlow Dragon Index represents the core holdings for the managed Ludlow China Fund, and provides investors with a general gauge of the funds core holdings and overall performance.
GRSR - below 1 times sales
GiraSolar (GRSR) - European solar company
- projecting $60 million in revenue for 2006
- projecting $80 million for 2007
- only 35 million shares outstanding
- way 'below' 1 times sales (P/S)
- .33 x .35
* most solar stocks trade at 10 x sales, but GRSR is not even trading at 0.5 x sales. Undervalued!
http://stockcharts.com/h-sc/ui?s=GRSR&p=D&yr=0&mn=6&dy=0&id=p17580455358
GRSR - below 1 times sales
GiraSolar (GRSR) - European solar company
- projecting $60 million in revenue for 2006
- projecting $80 million for 2007
- only 35 million shares outstanding
- way 'below' 1 times sales (P/S)
- .33 x .35
* most solar stocks trade at 10 x sales, but GRSR is not even trading at 0.5 x sales. Undervalued!
http://stockcharts.com/h-sc/ui?s=GRSR&p=D&yr=0&mn=6&dy=0&id=p17580455358
10 times sales = $100 million
If they are projecting at least around $10 million, then at 10 times sales CBPC would have a market cap of around $100 million. Based on around 90 million shares out that's $1.00+
But that's based on the share count staying the same.
Even at just 5 times sales that's $50 million market cap, or around $0.60 a share.
$3 million additional....
...additional. So they anticipate more then $3 million for 2007, that's already 100% above 2006 revenues with just this deal.
CBPC - News out! (.088 x .09)
China Biopharma Signed LOI to Acquire All the Interest of a Chinese Regional Pharmaceutical Distribution Company
- Acquisition Would Bring $3 Million Additional Revenue in 2007
PRINCETON, N.J., June 12 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced that its China operation subsidiary, Hainan CITIC Biopharmaceutical Development Co., Ltd. ('HCBP') has signed a letter of intent to acquire 100% of the interest of Beijing Tiancheng Haixin Pharmaceutical Co., Ltd. ('BTHP'), a regional distribution company headquartered in Beijing, China. The company believes that the acquisition will expand CBPC's presence in the Northern region of China with BTHP's well established distribution licenses and logistic facilities. The acquisition would also add direct distribution channels into 175 hospitals in the region. Currently, the main customers of HCBP are local Chinese CDCs. This acquisition would bring $3 million additional revenue in 2007 and $6 million in 2008 into HCBP's current revenue source.
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cbpc&sid=0&o_symb=cbpc&f...
.104 = 50 day MA
Looks like .104 will be a critical test. If CBPC can break above .104 it could spike and signal a move back into the .20's....we shall see.
http://stockcharts.com/h-sc/ui?s=CBPC&p=D&yr=0&mn=9&dy=0&id=p22657853461
CBPC - .089 x .09 (+ 38%)
CBPC ---> running
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=cbpc&sid=0&o_symb=cbpc&f...
you have to talk to Peter....
from my understanding is that GRSR has alot of news to announce, but Peter Klamka does not want to put them out.
University Project Izmir Turkey (Nov 2005)
http://www.girasolar.com.tr/img/projects/Izmir/
I agree with both your points
Lot to make back up. Hoping to see 10K soon.
NEST Energy - GRSR - US Panels
from the NEST Energy website.
-------
NEST sells small solar power systems, solar panels and other components to individuals and government agencies for use in solar energy systems. We carry a full line of panels, invertors and other solar system components.
Solar Panels
Our photovoltaic panels are manufactured in the U.S. by Girasolar, a company with over two decades experience in the solar energy industry.
http://www.nestenergysystems.com/solarcomponents.htm
2007 guidance on track...
from my talking with the company is that they werent able to recognize all the revenue from China BioPharma and thus the dissapointing 10Q. But, have been told that they are still comfortable with $10 million revenue guidance (or around that area) for fiscal 2007.
If that's the case (1) they should PR that, and (2) the next 10Q's should show a dramatic increase in revenues. May be worth playing some here to sell in mid-teens and see where the rest goes.
GRSR ---> do the math!
Shares outstanding = 35 million
Share Price = $0.40
Market Cap = $14 million
2006 Revenues = $60 million
* 2007 Projected Revenue = $80 million
With 35 mill shares outstanding, and at .40 a share, GRSR has a market cap of $14 million.
$14 million mrkt cap on a company doing $60 million in revenue, $1 million + in gross profit, and projected $80 million in revenues for 2007.
Do the math!
.35 x .37
$14 million market cap?
With 35 mill shares outstanding, and at .40 a share, GRSR has a market cap of $14 million.
$14 million mrkt cap on a company doing $60 million in revenue, $1 million+ in gross profit, and projected $80 million for 2007.
Do the math!
GRSR - European solar company
GiraSolar Inc. to Present at Intersolar 2007 Trade Show
GiraSolar Will Exhibit at the World's Major Solar Event of 2007, Intersolar 2007, Occurring June 21st Through June 23rd in Freiburg, Germany
DEVENTER, THE NETHERLANDS, Jun 04, 2007 (MARKET WIRE via COMTEX) -- GiraSolar Inc. (PINKSHEETS: GRSR), an umbrella organization for subsidiaries, partners, and affiliated entities active in the field of solar energy product development, production, and application, today announced that GiraSolar has once again been selected to exhibit at the Intersolar 2007 international trade fair in Freiburg, Germany.
Intersolar 2007 is Europe's largest international trade fair for solar technology, focusing on photovoltaics, solar thermal technology, and solar architecture. Intersolar 2007 is the only European solar technology trade fair which has been recognized as an international trade fair by both the German Trade Fair Industry Association (AUMA) and the World Organization for Trade Fairs and Exhibitions (UFI).
Compared with last year, it is expected that the number of exhibitors at the trade fair will have increased from 454 to 600, while the exhibition space will have been expanded from 26,000 square metres to 34,000 square metres. A new visitor record is also expected, with 26,000 visitors from more than 90 countries. This further underlines Intersolar's status as the meeting place of the international solar industry and highlights GiraSolar's importance in participating in the event.
Peter Klamka, President of GiraSolar, commented, "The decision to again exhibit in Freiburg at Intersolar 2007 is in the strategic interest of GiraSolar as a whole. It is an excellent opportunity to both strengthen and create industry relations and to present cutting edge GiraSolar solutions to industry partners."
Besides exhibiting at Intersolar, GiraSolar has also presented this year at several of the most important trade shows and conferences in the EU, which currently represents 66% of the world solar market. GiraSolar's focus has been on exhibitions in fast growing markets with substantial generic support to investors in solar energy systems. GiraSolar presented itself at exhibitions in Italy, Spain, and Greece and also at promising target countries in Central and Eastern Europe.
Wieland Koornstra, CEO of GiraSolar, further stated: "With at least one exhibition per month over the past half year, GiraSolar is executing its strategy to swiftly become well-known in promising and relatively new markets. Better visibility of GiraSolar is also part of our efforts to move closer to larger end users with the intention to capitalize on the extensive solar engineering capabilities of GiraSolar."
About GiraSolar, Inc.:
GiraSolar, Inc. is a US-Dutch holding company based in Ann Arbor with its operational HQ in Deventer, The Netherlands, through GiraSolar BV. It is an umbrella organization for subsidiaries, partners, and affiliated entities, active in the field of solar energy product development, production, and application. GiraSolar's three subsidiaries consist of 100% owned DutchSolar B.V., 51% owned GiraSolar Turkey Ltd. Ste. (GST), and 100% owned GiraMundo B.V. The group focuses with its business activities on silicon, solar cells, solar modules and solar energy systems.
GRSR - $60 mil revs vs. $14 mil mrkt cap
GiraSolar (GRESR) - European solar company
- to report $60 million in revenue for 2006
- projecting $80 million in revenue for 2007
- only 35 million outstanding
- market cap of only $14 million
way undervalued!
GRSR - $60 mill in revs, $14 mill mrkt cap
Looks like GRSR has hit a bottom.
- Expecting to post $60 million in revenue for 2006 in next week or so.
- Projecting $80 million for 2007.
- Only 35 million outstanding.
- $14 mill market cap, undervalued
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=grsr&sid=0&o_symb=grsr&f...